product summary
company name :
Cell Signaling Technology
product type :
antibody
product name :
EGF Receptor Antibody
catalog :
2232
clonality :
polyclonal
host :
domestic rabbit
conjugate :
nonconjugated
reactivity :
human, mouse, rat
application :
western blot, immunohistochemistry, immunocytochemistry, immunoprecipitation, flow cytometry, reverse phase protein lysate microarray, other
citations: 34
Published Application/Species/Sample/DilutionReference
  • western blot; human; fig 4d
Moon S, Lee H, Kim S, Hong J, Chun S, Lee H, et al. Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells. BMC Cancer. 2021;21:931 pubmed publisher
  • western blot; human; 1:1000; loading ...; fig 1l
Tripathi P, Guo H, Dreser A, Yamoah A, Sechi A, Jesse C, et al. Pathomechanisms of ALS8: altered autophagy and defective RNA binding protein (RBP) homeostasis due to the VAPB P56S mutation. Cell Death Dis. 2021;12:466 pubmed publisher
  • western blot; human; 1:1000; loading ...; fig 6b
Gao S, Gao L, Wang S, Shi X, Yue C, Wei S, et al. ATF3 Suppresses Growth and Metastasis of Clear Cell Renal Cell Carcinoma by Deactivating EGFR/AKT/GSK3β/β-Catenin Signaling Pathway. Front Cell Dev Biol. 2021;9:618987 pubmed publisher
  • western blot; human; loading ...; fig 1a
Ni W, Chen Z, Zhou X, Yang R, Yu M, Lu J, et al. Targeting Notch and EGFR signaling in human mucoepidermoid carcinoma. Signal Transduct Target Ther. 2021;6:27 pubmed publisher
  • western blot; human; 1:1000; loading ...; fig 1
Wang Q, Gavin W, Masiello N, Tran K, Laible G, Shepherd P. Cetuximab produced from a goat mammary gland expression system is equally efficacious as innovator cetuximab in animal cancer models. Biotechnol Rep (Amst). 2020;28:e00533 pubmed publisher
  • western blot; human; loading ...; fig s2
Greer Y, Gilbert S, Gril B, Narwal R, Peacock Brooks D, Tice D, et al. MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer. Breast Cancer Res. 2019;21:27 pubmed publisher
  • western blot; human; loading ...; fig 1c
Unni A, Harbourne B, Oh M, Wild S, Ferrarone J, Lockwood W, et al. Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells. elife. 2018;7: pubmed publisher
  • other; human; loading ...; fig 4c
Ng P, Li J, Jeong K, Shao S, Chen H, Tsang Y, et al. Systematic Functional Annotation of Somatic Mutations in Cancer. Cancer Cell. 2018;33:450-462.e10 pubmed publisher
  • western blot; human; 1:1000; fig 1a
Park G, Kim D. Cigarette smoke-induced EGFR activation promotes epithelial mesenchymal migration of human retinal pigment epithelial cells through regulation of the FAK-mediated Syk/Src pathway. Mol Med Rep. 2018;17:3563-3574 pubmed publisher
  • western blot; human; loading ...; fig 2b
Yu R, Longo J, van Leeuwen J, Mullen P, Ba Alawi W, Haibe Kains B, et al. Statin-Induced Cancer Cell Death Can Be Mechanistically Uncoupled from Prenylation of RAS Family Proteins. Cancer Res. 2018;78:1347-1357 pubmed publisher
  • western blot; human; 1:1000; loading ...; fig 8c
Zeng L, Kang R, Zhu S, Wang X, Cao L, Wang H, et al. ALK is a therapeutic target for lethal sepsis. Sci Transl Med. 2017;9: pubmed publisher
  • western blot; human; loading ...; fig 1b
Vaishnavi A, Schubert L, Rix U, Marek L, Le A, Keysar S, et al. EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases. Cancer Res. 2017;77:3551-3563 pubmed publisher
  • reverse phase protein lysate microarray; human; loading ...; fig st6
Cherniack A, Shen H, Walter V, Stewart C, Murray B, Bowlby R, et al. Integrated Molecular Characterization of Uterine Carcinosarcoma. Cancer Cell. 2017;31:411-423 pubmed publisher
  • western blot; human; loading ...; fig 2a
  • western blot; mouse; loading ...; fig 2b
Shizu R, Osabe M, Perera L, Moore R, Sueyoshi T, Negishi M. Phosphorylated Nuclear Receptor CAR Forms a Homodimer To Repress Its Constitutive Activity for Ligand Activation. Mol Cell Biol. 2017;37: pubmed publisher
  • western blot; human; loading ...
Hill S, Nesser N, Johnson Camacho K, Jeffress M, Johnson A, Boniface C, et al. Context Specificity in Causal Signaling Networks Revealed by Phosphoprotein Profiling. Cell Syst. 2017;4:73-83.e10 pubmed publisher
  • western blot; human; 1:1000; loading ...; fig 3
Kneissl J, Hartmann A, Pfarr N, Erlmeier F, Lorber T, Keller S, et al. Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines. J Cancer Res Clin Oncol. 2017;143:573-600 pubmed publisher
  • western blot; human; 1:1000; tbl s6
Mair B, Konopka T, Kerzendorfer C, Sleiman K, Salic S, Serra V, et al. Gain- and Loss-of-Function Mutations in the Breast Cancer Gene GATA3 Result in Differential Drug Sensitivity. PLoS Genet. 2016;12:e1006279 pubmed publisher
  • western blot; human; loading ...; fig 2f
Im J, Yoon S, Kim B, Ban H, Won K, Chung K, et al. DNA damage induced apoptosis suppressor (DDIAS) is upregulated via ERK5/MEF2B signaling and promotes ?-catenin-mediated invasion. Biochim Biophys Acta. 2016;1859:1449-1458 pubmed publisher
  • western blot; human; 1:1000; loading ...; fig 6a
Carino A, Graziosi L, D Amore C, Cipriani S, Marchianò S, Marino E, et al. The bile acid receptor GPBAR1 (TGR5) is expressed in human gastric cancers and promotes epithelial-mesenchymal transition in gastric cancer cell lines. Oncotarget. 2016;7:61021-61035 pubmed publisher
  • western blot; human; 1:1000; fig s2
Deblois G, Smith H, Tam I, Gravel S, Caron M, Savage P, et al. ERR? mediates metabolic adaptations driving lapatinib resistance in breast cancer. Nat Commun. 2016;7:12156 pubmed publisher
  • western blot; human; loading ...; fig 4f
Lin S, Choe J, Du P, Triboulet R, Gregory R. The m(6)A Methyltransferase METTL3 Promotes Translation in Human Cancer Cells. Mol Cell. 2016;62:335-345 pubmed publisher
  • western blot; human; 1:500; fig 3
Jahani Asl A, Yin H, Soleimani V, Haque T, Luchman H, Chang N, et al. Control of glioblastoma tumorigenesis by feed-forward cytokine signaling. Nat Neurosci. 2016;19:798-806 pubmed publisher
  • western blot; human; 1:1000; loading ...; fig 4b
Huang M, Liu T, Ma P, Mitteer R, Zhang Z, Kim H, et al. c-Met-mediated endothelial plasticity drives aberrant vascularization and chemoresistance in glioblastoma. J Clin Invest. 2016;126:1801-14 pubmed publisher
  • western blot; human; fig 4
Kabe Y, Nakane T, Koike I, Yamamoto T, Sugiura Y, Harada E, et al. Haem-dependent dimerization of PGRMC1/Sigma-2 receptor facilitates cancer proliferation and chemoresistance. Nat Commun. 2016;7:11030 pubmed publisher
  • western blot; human; fig 4
Hayashi H, Al Mamun A, Sakima M, Sato M. Activator of G-protein signaling 8 is involved in VEGF-mediated signal processing during angiogenesis. J Cell Sci. 2016;129:1210-22 pubmed publisher
  • flow cytometry; human; 2 ug/ml; fig 1
Evans M, Sauer S, Nath S, Robinson T, Morse M, Devi G. X-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity. Cell Death Dis. 2016;7:e2073 pubmed publisher
  • western blot; human; fig 1
Yoshida T, Song L, Bai Y, Kinose F, Li J, Ohaegbulam K, et al. ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. PLoS ONE. 2016;11:e0147344 pubmed publisher
  • immunocytochemistry; human; fig 1
Salova A, Belyaeva T, Leontieva E, Zlobina M, Kharchenko M, Kornilova E. Quantum dots implementation as a label for analysis of early stages of EGF receptor endocytosis: a comparative study on cultured cells. Oncotarget. 2016;7:6029-47 pubmed publisher
  • western blot; human; fig 4
Kitatani K, Usui T, Sriraman S, Toyoshima M, Ishibashi M, Shigeta S, et al. Ceramide limits phosphatidylinositol-3-kinase C2β-controlled cell motility in ovarian cancer: potential of ceramide as a metastasis-suppressor lipid. Oncogene. 2016;35:2801-12 pubmed publisher
  • western blot; rat; 1:1000
Maurya S, Mishra J, Abbas S, Bandyopadhyay S. Cypermethrin Stimulates GSK3β-Dependent Aβ and p-tau Proteins and Cognitive Loss in Young Rats: Reduced HB-EGF Signaling and Downstream Neuroinflammation as Critical Regulators. Mol Neurobiol. 2016;53:968-82 pubmed publisher
Fell S, Li S, Wallis K, Kock A, Surova O, Rraklli V, et al. Neuroblast differentiation during development and in neuroblastoma requires KIF1B?-mediated transport of TRKA. Genes Dev. 2017;31:1036-1053 pubmed publisher
Sommer A, Hermawan A, Mickler F, Ljepoja B, Knyazev P, Bräuchle C, et al. Salinomycin co-treatment enhances tamoxifen cytotoxicity in luminal A breast tumor cells by facilitating lysosomal degradation of receptor tyrosine kinases. Oncotarget. 2016;7:50461-50476 pubmed publisher
Krüwel T, Nevoltris D, Bode J, Dullin C, Baty D, Chames P, et al. In vivo detection of small tumour lesions by multi-pinhole SPECT applying a (99m)Tc-labelled nanobody targeting the Epidermal Growth Factor Receptor. Sci Rep. 2016;6:21834 pubmed publisher
Kozlova N, Samoylenko A, Drobot L, Kietzmann T. Urokinase is a negative modulator of Egf-dependent proliferation and motility in the two breast cancer cell lines MCF-7 and MDA-MB-231. Mol Carcinog. 2016;55:170-81 pubmed publisher
product information
SKU :
2232L
Product-Name :
EGF Receptor Antibody
Size :
300 ul
Price-(USD) :
574 USD
Species-x-Reactivity :
H, M, R, Mk
Applications :
Immunoprecipitation
Product-Category :
RTK
Shipping-Temp :
AMBIENT
Storage-Temp :
-20°C
Product-Type :
Polyclonal Antibody
MW :
175
Host :
Rabbit
Target :
EGFR
Primary-Protein :
EGFR
Alt-Names :
EGFR,ERBB,ERBB1,Epidermal growth factor receptor,HER1,PIG61,Proto-oncogene c-ErbB-1,Receptor tyrosine-protein kinase erbB-1,avian erythroblastic leukemia viral (v-erb-b) oncogene homolog,cell growth inhibiting protein 40,cell proliferation-inducing protein 61,epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian),mENA
company information
Cell Signaling Technology
3 Trask Lane
Danvers, MA 01923
info@cellsignal.com
https://www.cellsignal.com
8776162355
headquarters: USA
Established in Beverly, MA in 1999, Cell Signaling Technology (CST) is a privately-owned company with over 400 employees worldwide. We are dedicated to providing innovative research tools that are used to help define mechanisms underlying cell function and disease. Since its inception, CST has become the world leader in the production of the highest quality activation-state and total protein antibodies utilized to expand knowledge of cell signaling pathways. Our mission is to deliver the world's highest quality research tools that accelerate progress in biological research and personalized medicine.